{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T08:12:56Z","timestamp":1784448776924,"version":"3.55.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015831","name":"Radius Health Inc.","doi-asserted-by":"publisher","award":["NCT01343004"],"award-info":[{"award-number":["NCT01343004"]}],"id":[{"id":"10.13039\/100015831","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The goal of treatment for women at high risk of fracture who have a T-score \u2264\u22122.5 is to mitigate fracture risk by achieving T-scores at least above \u22122.5. In the ACTIVE trial, 2463 women with osteoporosis aged 49-86\u00a0yr were treated for 18 mo with abaloparatide (80\u00a0\u03bcg), teriparatide (20\u00a0\u03bcg), or placebo. In ACTIVExtend, eligible women from the abaloparatide and placebo groups received weekly treatment with 70\u00a0mg of alendronate for 2 additional years. This post hoc analysis of ACTIVE and ACTIVExtend included women with baseline TH or LS T-scores \u2264\u22122.5. Logistic regression was used to predict the probability of achieving a T-score &amp;gt;\u22122.5 at the TH or LS during 18 mo of treatment with abaloparatide or teriparatide and during 3.5\u00a0yr with the sequence of abaloparatide\/alendronate compared to placebo\/alendronate. At baseline, 23% and 74% of women enrolled in ACTIVE had T-scores \u2264\u22122.5 at the TH and LS, respectively. Over 18 mo of treatment, more than 50% of women were likely to achieve TH T-scores &amp;gt;\u22122.5, with baseline TH T-scores as low as \u22122.7 for both abaloparatide and teriparatide. More than 50% of women were predicted to achieve an LS T-score &amp;gt;\u22122.5 with a baseline LS T-score as low as \u22123.3 for abaloparatide or \u22123.2 on teriparatide. Over 3.5\u00a0yr of sequential treatment with abaloparatide\/alendronate, &amp;gt;50% of women with baseline TH T-scores \u2265\u22122.9 and LS T-scores \u2265\u22123.5 were predicted to achieve T-scores &amp;gt;\u22122.5, respectively. A patient\u2019s BMD at baseline and the probability of achieving target T-scores with treatment should be considered when determining that treatment should be initiated in patients at high or very high risk of fracture.<\/jats:p>","DOI":"10.1093\/jbmr\/zjaf053","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T12:22:46Z","timestamp":1744374166000},"page":"773-778","source":"Crossref","is-referenced-by-count":7,"title":["Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-6616","authenticated-orcid":false,"given":"Felicia","family":"Cosman","sequence":"first","affiliation":[{"name":"Department of Medicine, Columbia University College of Physicians and Surgeons , New York, NY 10032 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce H","family":"Mitlak","sequence":"additional","affiliation":[{"name":"Clinical Development, Radius Health Inc. , Boston, MA 02210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-9836","authenticated-orcid":false,"given":"Yamei","family":"Wang","sequence":"additional","affiliation":[{"name":"Biostatistics, Radius Health Inc. , Boston, MA 02210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leny","family":"Pearman","sequence":"additional","affiliation":[{"name":"Field Medical, Radius Health Inc , Boston, MA 02210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9908-4907","authenticated-orcid":false,"given":"Carolina A","family":"Moreira","sequence":"additional","affiliation":[{"name":"Endocrine Division (SEMPR), Federal University of Parana , Curitiba, PR 80060-000 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2026-9587","authenticated-orcid":false,"given":"E Michael","family":"Lewiecki","sequence":"additional","affiliation":[{"name":"Division of Metabolic Bone Diseases, University of New Mexico Health Sciences Center and New Mexico Clinical Research & Osteoporosis Center , Albuquerque, NM 87106 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R","family":"Cummings","sequence":"additional","affiliation":[{"name":"San Francisco Coordinating Center, California Pacific Medical Center Research Institute , San Francisco, CA 94158 ,","place":["United States"]},{"name":"Department of Epidemiology and Biostatistics, University of California , San Francisco, CA 94158 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"2025060307263341400_ref1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","article-title":"Goal-directed osteoporosis treatment: ASBMR\/BHOF Task Force Position Statement 2024","volume":"39","author":"Cosman","year":"2024","journal-title":"J Bone Miner Res"},{"key":"2025060307263341400_ref2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2025060307263341400_ref3","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"2025060307263341400_ref4","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2014-1971","article-title":"Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?","volume":"99","author":"Cosman","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2025060307263341400_ref5","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/jbmr.3996","article-title":"T-score as an indicator of fracture risk during treatment with romosozumab or alendronate in the ARCH trial","volume":"35","author":"Cosman","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2025060307263341400_ref6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/jbmr.3722","article-title":"Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment","volume":"34","author":"Ferrari","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2025060307263341400_ref7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"key":"2025060307263341400_ref8","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"2025060307263341400_ref9","first-page":"e1300","article-title":"Profile of abaloparatide and its potential in the treatment of postmenopausal osteoporosis","volume":"9","author":"Tella","year":"2017","journal-title":"Cureus"},{"key":"2025060307263341400_ref10","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2025060307263341400_ref11","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.eprac.2024.01.014","article-title":"Treatment sequence for osteoporosis","volume":"30","author":"Cosman","year":"2024","journal-title":"Endocr Pract"},{"key":"2025060307263341400_ref12","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10546","article-title":"Romosozumab followed by antiresorptive treatment increases the probability of achieving bone mineral density treatment goals","volume":"5","author":"Cosman","year":"2021","journal-title":"JBMR Plus"},{"key":"2025060307263341400_ref13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"2025060307263341400_ref14","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/jbmr.4719","article-title":"The efficacy and safety of Abaloparatide-SC in men with osteoporosis: a randomized clinical trial","volume":"37","author":"Czerwinski","year":"2022","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjaf053\/62914489\/zjaf053.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjaf053\/62914489\/zjaf053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjaf053\/62914489\/zjaf053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T11:26:40Z","timestamp":1748950000000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/40\/6\/773\/8111442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,11]]},"published-print":{"date-parts":[[2025,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjaf053","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,4,11]]}}}